Inventor · disambiguated record
Claudia Wagner
Also filed as: WAGNER CLAUDIA
49 granted patents·25 pending applications·309 citations·filing 2016–2025
98Inventor score
Top patents by PatentIndex Score
74 records- 0199US11324812B2Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2021·Granted May 10, 2022·11 cites·20 claims
- 0299US11071773B2Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2021·Granted Jul 27, 2021·8 cites·20 claims
- 0399US11027002B2Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2020·Granted Jun 8, 2021·8 cites·20 claims
- 0499US10898560B2Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2020·Granted Jan 26, 2021·11 cites·20 claims
- 0599US10898559B2Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2020·Granted Jan 26, 2021·11 cites·20 claims
- 0699US10526389B2Peptides and combinations of peptides for use in immunotherapy against lung cancer, including NSCLC and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2019·Granted Jan 7, 2020·14 cites·20 claims
- 0798US11116826B2Peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2021·Granted Sep 14, 2021·3 cites·20 claims
- 0898US11111294B2T cell receptors and immune therapy using the sameIMMATICS BIOTECHNOLOGIES GMBH·Filed 2020·Granted Sep 7, 2021·11 cites·15 claims
- 0998US10925948B2Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2016·Granted Feb 23, 2021·12 cites·23 claims
- 1098US10723796B2T cell receptors and immune therapy using the sameIMMATICS BIOTECHNOLOGIES GMBH·Filed 2019·Granted Jul 28, 2020·22 cites·20 claims
- 1198US10668138B1Peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2020·Granted Jun 2, 2020·4 cites·20 claims
- 1298US10590194B2T cell receptors and immune therapy using the sameIMMATICS BIOTECHNOLOGIES GMBH·Filed 2018·Granted Mar 17, 2020·23 cites·17 claims
- 1398US10577402B2Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2019·Granted Mar 3, 2020·12 cites·17 claims
- 1498US10550167B2Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2019·Granted Feb 4, 2020·12 cites·17 claims
- 1597US11007257B2Peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2020·Granted May 18, 2021·3 cites·20 claims
- 1697US11007258B2Peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2020·Granted May 18, 2021·3 cites·20 claims
- 1797US10898561B2Peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2020·Granted Jan 26, 2021·3 cites·20 claims
- 1897US10800832B2T cell receptors and immune therapy using the same against prame positive cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2019·Granted Oct 13, 2020·19 cites·14 claims
- 1997US10725044B2T cell receptors and immune therapy using the sameIMMATICS BIOTECHNOLOGIES GMBH·Filed 2018·Granted Jul 28, 2020·12 cites·30 claims
- 2097US10702609B2T cell receptors and immune therapy using the sameIMMATICS BIOTECHNOLOGIES GMBH·Filed 2019·Granted Jul 7, 2020·14 cites·33 claims
- 2197US10662233B2Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2019·Granted May 26, 2020·11 cites·20 claims
- 2297US10527623B2T cell receptors and immune therapy using the sameIMMATICS BIOTECHNOLOGIES GMBH·Filed 2017·Granted Jan 7, 2020·13 cites·9 claims
- 2396US10792350B2Peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2020·Granted Oct 6, 2020·3 cites·20 claims
- 2496US10729755B1Peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2020·Granted Aug 4, 2020·3 cites·20 claims
- 2596US10618956B2Engineered T cell receptors and immune therapy using the sameIMMATICS BIOTECHNOLOGIES GMBH·Filed 2018·Granted Apr 14, 2020·13 cites·16 claims
- 2696US10576135B2Peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2019·Granted Mar 3, 2020·5 cites·20 claims
- 2795US11072645B2T cell receptors with improved pairingIMMATICS BIOTECHNOLOGIES GMBH·Filed 2017·Granted Jul 27, 2021·10 cites·5 claims
- 2895US10561718B2Peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2019·Granted Feb 18, 2020·4 cites·20 claims
- 2994US10889645B2Engineered T cell receptors and immune therapy using the sameIMMATICS BIOTECHNOLOGIES GMBH·Filed 2020·Granted Jan 12, 2021·3 cites·20 claims
- 3094US10449239B1Peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2019·Granted Oct 22, 2019·3 cites·20 claims
- 3191US10874731B2T cell receptors and immune therapy using the sameIMMATICS BIOTECHNOLOGIES GMBH·Filed 2017·Granted Dec 29, 2020·4 cites·15 claims
- 3290US11840577B2Antigen binding proteins specifically binding MAGE-AIMMATICS BIOTECHNOLOGIES GMBH·Filed 2020·Granted Dec 12, 2023·2 cites·9 claims
- 3390US10357551B2Peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2018·Granted Jul 23, 2019·7 cites·21 claims
- 3490US2025154246A1Novel t cell receptors and immune therapy using the sameIMMATICS BIOTECHNOLOGIES GMBH·Filed 2024·Application pending·0 cites
- 3589US11236145B2T cell receptors and immune therapy using the same against PRAME positive cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2018·Granted Feb 1, 2022·3 cites·25 claims
- 3689US11111286B2T cell receptors and immune therapy using the same against PRAME positive cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2019·Granted Sep 7, 2021·3 cites·20 claims
- 3788US10076560B2Peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2016·Granted Sep 18, 2018·6 cites·13 claims
- 3887US12295995B2Peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2022·Granted May 13, 2025·0 cites·19 claims
- 3987US12295994B2Peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2022·Granted May 13, 2025·0 cites·19 claims
- 4087US12295996B2Peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2022·Granted May 13, 2025·0 cites·15 claims
- 4185US2025235519A1Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2025·Application pending·0 cites
- 4284US2022193212A1Novel peptides and combination of peptides for use in immunotherapy against lung cancer, including nsclc and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2022·Application pending·0 cites
- 4384US2022211833A1Novel peptides and combination of peptides for use in immunotherapy against lung cancer, including nsclc and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2022·Application pending·0 cites
- 4484US2022313805A1Novel peptides and combination of peptides for use in immunotherapy against lung cancer, including nsclc and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2022·Application pending·0 cites
- 4584US2022184193A1Novel peptides and combination of peptides for use in immunotherapy against lung cancer, including nsclc and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2022·Application pending·0 cites
- 4684US2022184194A1Novel peptides and combination of peptides for use in immunotherapy against lung cancer, including nsclc and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2022·Application pending·0 cites
- 4784US2024228611A1Novel engineered t cell receptors and immune therapy using the sameIMMATICS BIOTECHNOLOGIES GMBH·Filed 2024·Application pending·0 cites
- 4883US12269881B2Antigen binding proteins specifically binding MAGE-AIMMATICS BIOTECHNOLOGIES GMBH·Filed 2023·Granted Apr 8, 2025·0 cites·8 claims
- 4981US12214025B2Peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2021·Granted Feb 4, 2025·0 cites·17 claims
- 5081US2024285779A1Novel t cell receptors and immune therapy using the sameIMMATICS BIOTECHNOLOGIES GMBH·Filed 2024·Application pending·0 cites
Showing the top 50 of 74 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Claudia Wagner files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →